
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is poised for strong growth in the coming years with sales expected to increase due to strong Q1 results, a rise in new patient starts, and progress on their Mint and Bihormonal pumps. However, there are risks such as potential competition, a recent FDA warning letter, and potential fluctuations in reported events with changes in reporting standards. With a favorable risk-reward profile and plans for FDA approval and launch of their Mint patch pump in 2027, BBNX has the potential to grow significantly.
Bears say
Beta Bionics is a promising commercial-stage medical device company with a strong focus on improving the treatment of diabetes and enhancing the lives of patients. Despite the recent pressure on stock prices, the company has reported strong Q1 results, with increased guidance, new patient additions, and better-than-expected pharmacy adds. Gross margin and sales force expansion are also progressing well, making it an attractive investment opportunity with a target price of $20.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares